Top Markets
#1 MowCat MowCat +776.52%
#2 龙虾 (Lobster) 龙虾 (Lobster) +81.61%
#3 Akedo Akedo +49.11%
#4 Magma Finance Magma Finance +41.92%
#5 DeXe DeXe +31.41%
#6 SIXSEVEN SIXSEVEN +29.75%
#7 Cortex Cortex +26.19%
#8 MarsCoin MarsCoin +25.84%
#9 Zignaly Zignaly +17.71%
#10 Staked ZIG Staked ZIG +17.54%
Coin of the day
MowCat MowCat
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Staidson (Beijing) BioPharmaceuticals Co., Ltd. Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Staidson (Beijing) BioPharmaceuticals Co., Ltd.

300204
Classificação em ações #7949
Staidson (Beijing) BioPharmaceuticals Co., Ltd. is a Chinese biopharmaceutical... Staidson (Beijing) BioPharmaceuticals Co., Ltd. is a Chinese biopharmaceutical company that specializes in the entire lifecycle of therapeutic drugs, from research and development to production and market distribution. Their product portfolio encompasses a variety of drug types, including advanced protein-based medicines like therapeutic monoclonal antibodies, innovative gene and cell therapies, and conventional chemical pharmaceuticals. The company's primary therapeutic areas address conditions related to the nervous system, infectious diseases, gastrointestinal health, the urinary system, and autoimmune disorders. Notably, Staidson has established a strategic partnership with Pivotal S.L. to conduct clinical trials in Europe for BDB-001, a monoclonal anti-C5a antibody, aimed at treating patients with severe, progressive COVID-19 caused by the SARS-CoV-2 virus. Founded in 2002, the company's headquarters are located in Beijing, China.
Preço da ação
$3.11
Valor de mercado
$1.41B
Variação (1 dia)
-1.97%
Variação (1 ano)
-57.22%
País
CN
Negociar Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204)

Categoria

Healthcare
Receita da Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204)
Receita em Aug 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Staidson (Beijing) BioPharmaceuticals Co., Ltd., a receita atual da empresa (TTM) é 0. Em 2026, a empresa obteve uma receita de 0 igual a a receita do ano 2026, que foi de 0. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Staidson (Beijing) BioPharmaceuticals Co., Ltd. de 2026 a 2026
Receita no final de cada ano
Ano Receita Alterar
Não há dados suficientes para as datas fornecidas.
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH